An IL-17 drug helped children with hard-to-treat juvenile arthritis

Most children with two of the harder-to-treat forms of juvenile arthritis responded to the drug ixekizumab within 16 weeks in the COSPIRIT-JIA trial, with about nine in ten of those new to biologic treatment meeting the standard improvement threshold [s1]. The result is encouraging for a group with few options, but it has to be read against how the trial was built: the headline figure came from children who all received ixekizumab, with no placebo or active comparator to measure against, so it shows that many improved — not how much of that improvement the drug itself caused [s1].

Juvenile idiopathic arthritis (JIA) is an umbrella term for chronic childhood arthritis. Two of its categories — enthesitis-related arthritis, where the inflammation centres on the points where tendons attach to bone, and juvenile psoriatic arthritis — are related to the adult spondyloarthritis and psoriatic-arthritis family, and a substantial share of children do not achieve lasting control on standard treatments including anti-inflammatories, methotrexate and the older biologic drugs [s1]. Ixekizumab blocks interleukin-17A, an inflammatory signal already targeted in adults with those conditions and in psoriasis [s1].

What the trial did

COSPIRIT-JIA is a multicentre, open-label, phase 3 study run by Eli Lilly, which makes ixekizumab [s1]. It enrolled children with enthesitis-related arthritis (aged 6 to under 18) or juvenile psoriatic arthritis (aged 2 to under 18) who had at least three actively inflamed joints and weighed at least 10 kg [s1]. All were treated with weight-based subcutaneous ixekizumab; a small group of biologic-naive children was randomly assigned to a reference arm of adalimumab, an established TNF- blocking biologic, to put the ixekizumab results in context rather than to pit the two drugs against each other in a powered comparison [s1].

The trial enrolled 101 patients between April 2021 and April 2024 — 81 on ixekizumab and 20 on adalimumab [s1]. The first 40 biologic-naive children were randomised 1:1 to the two drugs, and a further 61 were assigned to ixekizumab [s1]. Of the 81 who received ixekizumab, 60 were new to biologic treatment and 21 had used one before; their median age was 14 years, 36 (44%) were female and 69 (85%) were White [s1]. The primary endpoint was the proportion of ixekizumab-treated children reaching a JIA-ACR30 response — at least 30% improvement across a set of standard disease measures — at week 16, estimated with a Bayesian analysis [s1].

What it found

Response rates were high. At week 16, 90% of the biologic-naive children on ixekizumab reached JIA-ACR30 (54 of 60; 95% credible interval 82.4 to 97.6), as did 86% of those who had used a biologic before (18 of 21; 70.7 to 100.0) [s1]. Treatment-emergent adverse events were mostly mild (46%) or moderate (36%), with no severe events reported, and the safety picture matched what ixekizumab has shown in adults with psoriatic arthritis and spondyloarthritis and in children with psoriasis [s1]. The investigators concluded that the drug was well tolerated and effective for children with these two JIA categories who are candidates for biologic therapy [s1].

How to read it

A 90% response rate reads like a near-cure, and it is where the design has to temper the enthusiasm. JIA-ACR30 is a modest bar — a 30% improvement, not remission — and, more importantly, the primary analysis was single-arm [s1]. In childhood arthritis, response rates measured without a control tend to overstate a drug's specific effect, because some children improve with time, with attention and with the anti-inflammatories and other care they continue to receive. The adalimumab reference group was small and was not designed to establish which drug is better, so COSPIRIT can say that most treated children improved, but not by how much ixekizumab beat doing something else [s1].

That is exactly the gap a controlled trial fills, and the IL-17 class already has one in these same two conditions. In the JUNIPERA trial, the related drug secukinumab was tested with a randomised-withdrawal design: children who responded during an open-label phase were then randomly assigned to keep the drug or switch to placebo, which isolates the drug's effect [s2]. There, flares occurred in 27% of children who stayed on secukinumab versus 55% who were switched to placebo, a statistically significant difference (hazard ratio 0.28, 95% CI 0.13 to 0.63) [s2]. That controlled contrast — roughly half the flare rate on the active drug — is the kind of evidence that quantifies benefit in a way a single-arm response rate cannot, and it is the reasonable backdrop for reading COSPIRIT's numbers as consistent with a real class effect rather than as a precise measure of one drug's power [s1][s2].

Related coverage has examined why psoriasis and its IL-17-driven inflammation carry systemic, whole-body consequences, a B-cell-depleting biologic tested in lupus, and what the trials actually show for paracetamol in back pain and osteoarthritis.

What to watch

COSPIRIT-JIA is ongoing, and longer follow-up will show whether the early responses hold and whether the safety profile stays clean with continued use [s1]. For families and clinicians, the practical value of the trial is that it brings a second targeted mechanism — IL-17 blockade — into evidence for two JIA categories that resist standard care; the open question its design leaves is the size of the advantage over the alternatives, which only a controlled comparison will settle [s1][s2].

This article describes research and is not medical advice. Treatment of juvenile arthritis is a decision for families and their paediatric rheumatologists.

Sources

• Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab — The Lancet Rheumatology, 2 March 2026
• Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial (JUNIPERA) — Annals of the Rheumatic Diseases, 12 August 2022